Inhibrx Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

17 Mar 2025

INBX

10-K: Inhibrx Biosciences Reports Strong Progress in Clinical Pipeline and Outlines Financial Strategy in 2024 10-K Filing

Inhibrx Biosciences highlights clinical advancements in its oncology pipeline and details its financial position and strategies in its 2024 annual report.